Event Title

CLINICAL AND PRE-CLINICAL EVALUATION OF THE EFFECT OF DIFFERENT TYPE OF BETA-CASEIN ON REDOX AND EPIGENETIC STATUS

Location

POSTER PRESENTATIONS

Start Date

12-2-2016 12:00 AM

Description

Objective. To investigate the effects of A1 vs A2 type of beta-casein containing diet on antioxidant GSH levels and inflammatory status in pre-clinical and clinical trials. Background. Alterations in GSH levels are reported in neurological, inflammatory diseases as well as immune dysfunction. Several studies in animals and humans involving supplementation with whey protein or whey protein isolates from milk have documented increases in plasma and tissue glutathione concentrations along with reductions in oxidative stress, while the effects of casein on GSH are as yet not clear. Methods. A pre-clinical study was performed using mouse and rabbit animal models fed on A1 and A2 beta-casein containing diet. The clinical study was performed in collaboration with researchers in China (NCT02406469 https://clinicaltrials.gov/ct2/show/NCT02406469). We collected liver, brain and gut tissues in our preclinical study, whereas serum GSH was measured in our clinical study. In both cases HPLC coupled to an electrochemical gradient detector was used to evaluate GSH levels. Results. In our preclinical study we observed significant decrease in GSH levels (indicating oxidative stress) in liver, gut and brain samples from animals (both mice and rabbit, p<0.05, N=12) fed on an A1 beta-casein containing diet as compared to animals fed on A2 beta-casein containing diet. Concurrently, we also observed elevated TNFalpha levels and NFkB levels in gut tissues of mice and rabbit on an A1 beta-casein containing diet as compared to animals fed on A2 beta-casein containing diet, indicating elevated inflammatory status (p<0.05, N=12). Similarly, in our clinical trial, human participants consuming A1 beta-casein containing milk had decreased GSH serum (p<0.05, N=45). Conclusion. Absorption of whey-derived cysteine supports GSH synthesis. BCM-7 opiate peptide, released from digestion of A1-type beta-casein, can restrict cysteine absorption and limit the extent of GSH synthesis, especially in sensitive individuals. Milk free of A1 beta-casein might be beneficial in these individuals. Grants. NIH R21, The a2 Milk Company.

This document is currently not available here.

Share

COinS
 
Feb 12th, 12:00 AM

CLINICAL AND PRE-CLINICAL EVALUATION OF THE EFFECT OF DIFFERENT TYPE OF BETA-CASEIN ON REDOX AND EPIGENETIC STATUS

POSTER PRESENTATIONS

Objective. To investigate the effects of A1 vs A2 type of beta-casein containing diet on antioxidant GSH levels and inflammatory status in pre-clinical and clinical trials. Background. Alterations in GSH levels are reported in neurological, inflammatory diseases as well as immune dysfunction. Several studies in animals and humans involving supplementation with whey protein or whey protein isolates from milk have documented increases in plasma and tissue glutathione concentrations along with reductions in oxidative stress, while the effects of casein on GSH are as yet not clear. Methods. A pre-clinical study was performed using mouse and rabbit animal models fed on A1 and A2 beta-casein containing diet. The clinical study was performed in collaboration with researchers in China (NCT02406469 https://clinicaltrials.gov/ct2/show/NCT02406469). We collected liver, brain and gut tissues in our preclinical study, whereas serum GSH was measured in our clinical study. In both cases HPLC coupled to an electrochemical gradient detector was used to evaluate GSH levels. Results. In our preclinical study we observed significant decrease in GSH levels (indicating oxidative stress) in liver, gut and brain samples from animals (both mice and rabbit, p<0.05, N=12) fed on an A1 beta-casein containing diet as compared to animals fed on A2 beta-casein containing diet. Concurrently, we also observed elevated TNFalpha levels and NFkB levels in gut tissues of mice and rabbit on an A1 beta-casein containing diet as compared to animals fed on A2 beta-casein containing diet, indicating elevated inflammatory status (p<0.05, N=12). Similarly, in our clinical trial, human participants consuming A1 beta-casein containing milk had decreased GSH serum (p<0.05, N=45). Conclusion. Absorption of whey-derived cysteine supports GSH synthesis. BCM-7 opiate peptide, released from digestion of A1-type beta-casein, can restrict cysteine absorption and limit the extent of GSH synthesis, especially in sensitive individuals. Milk free of A1 beta-casein might be beneficial in these individuals. Grants. NIH R21, The a2 Milk Company.